#FLOWJO ENVOY FOR FREE#
Download this IPO Watch List today for free > Four others are a little less obvious but already show jaw-dropping growth. One has driven from 0 to a $68 billion valuation in 8 years. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. The stock added roughly 12% over the last three months.īefore looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. The stock has a solid one-year return of around 80%.Īccelerate Diagnostics has an expected long-term adjusted earnings growth of 30%.
![flowjo envoy flowjo envoy](https://docs.flowjo.com/wp-content/uploads/sites/8/2016/11/WFDetail-Callouts-1.png)
Inogen has a long-term expected earnings growth rate of 17.5%. The stock added roughly 32.8% over the last three months. You can see the complete list of today’s Zacks #1 Rank stocks here.Īlign Technology has an expected long-term adjusted earnings growth of almost 24.1%. Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). On the flipside, lower demand for healthcare products, intensifying competition, significant exposure to foreign exchange volatility and higher debt levels pose major headwinds.īetter-ranked medical stocks are Align Technology, Inc. Additionally, its expansion plans, especially in the emerging overseas markets and the acquisition-driven strategy hold considerable promise. Going forward, BD’s focus on product launches is a significant catalyst in our view. The combination will also enable researchers to improve their workflow, collaborations and store their data in the cloud and share single-cell analysis information in real-time.īased in Franklin Lakes, NJ, Becton, Dickinson is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. This would enable the users to achieve a measurement of up to 50 different characteristics of a single cell. The collaboration would bring together Becton’s proprietary FACSymphony cell analyzer and FlowJo Envoy to enable scientists to collaborate, coordinate and execute high-parameter single-cell experiments seamlessly in real-time. The current year estimate for the stock stands at 53 cents per share. The above factor indicates chances of a recovery. The estimate revision trend seems favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement. This, together with a long-term expected earnings growth rate of 11.29%, instills confidence in investors. The current level compares favorably with the S&P 500’s return of 1.26% over the same time frame.
![flowjo envoy flowjo envoy](https://docs.flowjo.com/wp-content/uploads/sites/8/2016/11/Search_Field_WflowDetail.png)
The company gained roughly 3.91%, which is higher than the Zacks categorized Medical/Dental-Supplies sub industry’s addition of almost 3.41%. Per the agreement, the companies would offer the cloud-based platform, FlowJo Envoy alongwith BD FACSymphony, a cell analyzer for their customers.īecton has had an impressive run on the bourse over the past one month.
![flowjo envoy flowjo envoy](https://docs.flowjo.com/wp-content/uploads/sites/8/2016/11/Explore-View.jpg)
![flowjo envoy flowjo envoy](https://docs.flowjo.com/wp-content/uploads/sites/8/2016/11/WFFilter-callouts-1.png)
Leading global medical technology company, Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has entered into an agreement with FlowJo, LLC, a life science informatics and data analysis company.